Amgen Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Amgen (AMGN) PT Lowered to $193 at Morgan Stanley Following 3Q
October 26, 2017 9:25 AM EDTMorgan Stanley lowered its price target on Amgen (NASDAQ: AMGN) to $193.00 (from $196.00) while maintaining a Overweight rating following the company's 3Q release. Total revenues were slightly above ($5.77B vs. $5.74B cons), as were COGS (+$10M) and SG&A (+$20M), with R&D... More
